Kontrol Technologies Corp., a specialist in smart buildings and cities through IoT, cloud and SaaS technology, has announced updates to its BioCloud technology platform.
BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, offices, retirement homes, hospitals, mass transportation and others.
For pilot deployments of its technology, Kontrol announced the following:
Successful pilot with Rowing Canada Aviron: Kontrol has completed a successful pilot using multiple BioCloud units in various training locations. Data from the BioCloud operation mirrored the independent PCR testing completed over the duration of the pilot.
Middle East Pilot: Following initial delays due to previously announced supply chain issues, Kontrol BioCloud commenced its operational pilot in the Middle East. To date BioCloud has sampled ambient air exposed to by more than 300 individuals in a medical screening facility. Current progress of the pilot has demonstrated successful collection of human RNA through real-time air sampling and monitoring applications. Independent PCR testing provided through the pilot partner has validated the samples collected. Kontrol is working with its pilot partner in the region to gain access to a Covid hospice or hospital for the next phase of the pilot.
Canadian Hospital Pilot: With the support of independent researchers, Kontrol BioCloud will launch its first large Canadian hospital pilot in Q2, 2021 and provide an update following the completion of the pilot.
Further, Kontrol announced it has recently added a new distribution partner in India on a non-exclusive basis. The company continues to focus on adding quality distribution partners to grow its global distribution platform.
Meanwhile, following the announcement of a Canadian lease finance program for BioCloud across Canada with RCAP leasing, the company said has commenced discussions for a similar U.S. based lease financing program for BioCloud sales in the U.S.
BioCloud distributors have expressed the interest in providing customers with a choice of an initial purchase versus an ongoing monthly payment. With a small initial deposit and a monthly payment of approximately $200 customers will have a flexible financing solution to add Kontrol BioCloud to their business and operations. At the end of the finance term customers will have a nominal buy-out.
Each BioCloud unit in operation logs thousands of data points daily in real-time. Through this data collection and monitoring scheme, Kontrol says it has been able to design advancements to the BioCloud technology. These advancements are considered fine-tuning and adaptive without requiring hardware changes.
The company notes an important advancement to the technology was achieved by fine tuning laser optics and new a new chemical bonding formulation. Based on laboratory testing, the new chemical bonding formulation has shown an increase of up to 10 times greater resolution than was previously capable.
"We continue to progress the BioCloud technology as a global solution for real-time viral detection and safer spaces," comments Paul Ghezzi, CEO of Kontrol Technologies Corp. "With units in the field collecting data, in real-time, we have completed another round of significant milestones. We are now in a position where we can showcase live operating results with distribution partners, customers, and other interested parties. Further the successful pilots and the data generated have been an important source of technology advancement. We also have our first distribution partner in India."
More information can be found at www.kontrolbiocloud.com.
